Critics knock JAMA study linking testosterone drugs to cardio risks
3rd April 2014
A study the FDA has cited as a reason to investigate the cardiovascular safety of testosterone drugs has come under heavy fire from critics. Physicians and researchers are calling for the November paper’s retraction, citing at least two corrections that they say compromise its credibility.
As MedPage Today reports, the Androgen Study Group, comprising more than 125 doctors, has sent a letter to Howard Bauchner, editor-in-chief of the Journal of the American Medical Association (JAMA), asking that a study that linked testosterone therapy to a greater risk of death, heart attack and stroke in some patients be pulled from the publication.
Read more at source article www.fiercepharma.com